A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure

by Daniel J. Lenihan, MD, Sarah A. Anderson, ACNP, Carrie Geisberg Lenneman, MD, Evan Brittain, MD, MSCI, James A.S. Muldowney, III, MD, Lisa Mendes, MD, Ping Z. Zhao, PhD, Jennifer Iaci, MS, Stephen Frohwein, MD, Ronald Zolty, MD, PhD, Andrew Eisen, MD, PhD, Douglas B. Sawyer, MD, PhD, Anthony O. Caggiano, MD, PhD
Published 2016-12-01